Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGA2115
- Development stage
- Phase 2
- Lead developer
- Angitia Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
AGA2115 is a first-in-class, humanized bispecific antibody developed by Angitia Biopharmaceuticals for the treatment of osteogenesis imperfecta (OI), a rare and life-threatening genetic skeletal disorder. The drug works by simultaneously neutralizing two key negative regulators of bone formation, sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), thereby increasing bone mass, improving bone strength and structure, and reducing skeletal fractures. Preclinical studies have demonstrated robust efficacy in restoring bone quality in disease models. The U.S. FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to AGA2115 for OI. It is currently being evaluated in Phase 1 clinical trials[1][2][3][4][6][7].
- Other names
- Humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1
02
Targets
DKK1 (Dickkopf-related protein 1)SOST (Sclerostin)
Beyond the preview
Go deeper on AGA2115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGA2115.